Although treatment with resmetirom significantly reduced steatosis in both the PNPLA3 GG variant and CC wild-type LAMPSs compared to their respective vehicle controls (Supplementary Figure S10B), a significantly greater reduction in steatosis was observed in the PNPLA3 CC wild-type LAMPS (∼33%) compared to the PNPLA3 GG variant (∼20%) (Figures 5B,C), indicating that resmetirom has better efficacy in the PNPLA3 CC wild-type LAMPS. The gene discussed is PNPLA3; the disease is steatosis.